Skip To Main Content
Peter Loftus on Muck Rack

Peter Loftus

Verified
Philadelphia
As seen in: The Wall Street Journal, MSN, Color Research & Application, The Wall Street Journal (Japan), Yahoo News, The Wall Street Journal (China), Yahoo Finance, MarketWatch, The Times, The Toronto Star, Flipboard and
Wall Street Journal @WSJ reporter - pharmaceuticals, medical devices, healthcare. peter.loftus@wsj.com. Author of The Messenger

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Pfizer's quarterly results beat expectations on cancer, heart drugs

|
By Katherine Hamilton Verified, Peter Loftus Verified
| MSN Verified
Pfizer reported better-than-expected second-quarter results, as rising sales of drugs for cancer and heart disease helped offset steep declines for Covid-19 products. The New York company also slightly raised the bottom end of its forecast range for full-year 2026 revenue. Pfizer shares were largely unchanged in premarket trading. Pfizer is trying to recover from a postpandemic hangover in which demand for its Covid-19 vaccine and treatment have plummeted.
Open in Who Shared Issue with article?

Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs

|
By Katherine Hamilton Verified, Peter Loftus Verified
| Yahoo Finance Verified
Sales of Pfizer's Comirnaty Covid vaccine dropped 34% in the quarter. - hannah beier/Reuters Pfizer reported better-than-expected second-quarter results, as rising sales of drugs for cancer and heart disease helped offset steep declines for Covid-19 products. The New York company also slightly raised the bottom end of its forecast range for full-year 2026 revenue. The AI Boom Is Transforming the American Economy Beyond Recognition Whirlpool Abandoned Its Global Ambitions.
Open in Who Shared Issue with article?

経口減量薬シェア争いはノボ優勢、リリーも反撃へ

|
By Peter Loftus Verified
| The Wall Street Journal (Japan) Verified
製薬業界で今、最も熾烈（しれつ）な争いが繰り広げられているのは経口肥満症治療薬だ。今のところは、米製薬大手イーライリリーがデンマークの製薬大手ノボ・ノルディスクにリードを許している。 リリーは経口肥満症治療薬「ファウンダヨ」を4月に発売したが、最新の週次データによると、新型経口薬の処方件数にファウンダヨが占める割合は約11％にとどまる。残りを占めているのは、1月に発売されたノボの経口肥満症治療薬「ウゴービ錠」だ。 Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Open in Who Shared Issue with article?
See all 1,298 licensed articles (1,407 Total)